DK1910839T3 - Gen TOM34 i forbindelse med coloncancer - Google Patents
Gen TOM34 i forbindelse med coloncancer Download PDFInfo
- Publication number
- DK1910839T3 DK1910839T3 DK06781857.5T DK06781857T DK1910839T3 DK 1910839 T3 DK1910839 T3 DK 1910839T3 DK 06781857 T DK06781857 T DK 06781857T DK 1910839 T3 DK1910839 T3 DK 1910839T3
- Authority
- DK
- Denmark
- Prior art keywords
- tom34
- cells
- polypeptide
- cell
- expression
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Fremgangsmåde til screening efter en forbindelse til behandling eller forhindring af coloncancer, hvilken fremgangsmåde omfatter følgende trin: (a) at bringe en testforbindelse i kontakt med et polypeptid, som kodes for af et polynukleotid af TOM34; (b) detektion af bindingsaktiviteten imellem polypeptidet og testforbindelsen; og (c) udvælgelse af den testforbindelse, som binder til polypeptidet.
2. Fremgangsmåde til screening efter en forbindelse til behandling eller forhindring af coloncancer, hvilken fremgangsmåde omfatter følgende trin: (a) at bringe kandidatforbindelser i kontakt med en celle, som eksprimerer TOM34; og (b) udvælgelse af den kandidatforbindelse, som reducerer eksprimeringsniveauet for TOM34 i sammenligning med eksprimeringsniveauet for TOM34 detekteret i fraværet af testforbindelsen.
3. Fremgangsmåde ifølge krav 2, hvor cellen omfatter en coloncancercelle.
4. Fremgangsmåde til screening efter en forbindelse til behandling eller forhindring af coloncancer, hvilken fremgangsmåde omfatter følgende trin: (a) at bringe en testforbindelse i kontakt med et polypeptid, som kodes for af et polynukleotid af TOM34; (b) detektion af den biologiske aktivitet for polypeptidet fra trin (a); og (c) udvælgelse af den testforbindelse, som undertrykker den biologiske aktivitet for polypeptidet, som kodes for af polynukleotidet af TOM34 i sammenligning med den biologiske aktivitet for polypeptidet detekteret under fraværet af testforbindelsen.
5. Fremgangsmåde til screening for en forbindelse til behandling eller forhindring af coloncancer, hvilken fremgangsmåde omfatter følgende trin: (a) at bringe en kandidatforbindelse i kontakt med en celle, i hvilken en vektor, som omfatter den transkriptionsregulerende region af TOM34 og et reportergen, som er eksprimeret under kontrol af den transkriptionsregulerende region, er indført; (b) måling af eksprimeringen eller aktiviteten af reportergenet; og (c) udvælgelse af den kandidatforbindelse, som reducerer eksprimeringen eller aktiviteten af det nævnte reportergen.
6. Antisense-sammensætning til anvendelse ved behandling eller forhindring af coloncancer i et subjekt, hvilken antisense-sammensætning omfatter en nukleotid-sekvens, som er komplementær med en kodningssekvens af TOM34. 7. siRNA-Sammensætning til anvendelse ved behandling eller forhindring af coloncancer i et subjekt, hvor den nævnte siRNA-sammensætning reducerer eksprimeringen af TOM34. 8. siRNA-Sammensætning til anvendelse i overensstemmelse med krav 7, hvor den nævnte siRNA omfatter sensestrengen omfattende en nukleotidsekvens ifølge SEQ ID NO: 48 eller SEQ ID NO: 52. 9. siRNA-Sammensætning til anvendelse i overensstemmelse med krav 8, hvor den nævnte siRNA har den generelle formel 5'-[A]-[B]-[A']-3', hvor [A] er en ribonukleotid-sekvens svarende til en sekvens ifølge SEQ ID NO: 48 eller SEQ ID NO: 52, [B] er en ribonukleotidsløjfesekvens bestående af 3 til 23 nukleotider og [A'j er en ribonukleotid-sekvens bestående af den komplementære sekvens af [A].
10. Antistof eller immunologisk aktivt fragment deraf, som binder til et protein af TOM34, til anvendelse ved behandling eller forhindring af coloncancer i et subjekt.
11. Vaccine omfattende (a) et polypeptid, som kodes for af en nukleinsyre af TOM34, (b) et immunologisk aktivt fragment af det nævnte polypeptid, eller (c) et polynukleotid, som koder for polypeptidet eller det immunologisk aktive fragment af (b), til anvendelse ved behandling eller forhindring af coloncancer i et subjekt.
12. Vaccine til anvendelse i overensstemmelse med krav 11, hvor det immunologisk aktive fragment er én eller begge af (i) decapeptid omfattende aminosyresekvensen ifølge SEQ ID NO: 7, og (ii) et peptid med cytotoksisk T-celle-inducerbarhed, hvor peptidet omfatter aminosyresekvensen ifølge SEQ ID NO: 7, hvor 1 eller 2 aminosyrer er substituerede eller tilføjede.
13. Polypeptid, polynukleotid, som koder for polypeptidet, eller en vektor omfattende polynukleotidet, hvor polypeptidet kodes for af TOM34 eller et immunologisk aktivt fragment af det nævnte polypeptid, til anvendelse ved inducering af en anti-tumor-immunitet, hvor polypeptidet, polynukleotidet eller vektoren bringes i kontakt med en antigen præsenterende celle.
14. In vitro fremgangsmåde til inducering af anti-tumor-immunitet, hvilken fremgangsmåde omfatter trinnet med at bringe en antigenpræsenterende celle i kontakt med vaccinen ifølge krav 11.
15. Polypeptid, polynukleotid eller vektor til anvendelse i overensstemmelse med krav 13 eller fremgangsmåden ifølge krav 14, hvor det immunologisk aktive fragment er én eller begge af (i) et decapeptid, som omfatter aminosyresekvensen ifølge SEQ ID NO: 7, og (ii) et peptid med cytotoksisk T-celle-inducerbarhed, hvor peptidet omfatter aminosyresekvensen ifølge SEQ ID NO: 7, i hvilken 1 eller 2 aminosyrer er substituerede eller tilføjede.
16. Decapeptid omfattende aminosyresekvensen ifølge SEQ ID NO: 7.
17. Peptid med cytotoksisk T-celle-inducerbarhed, hvor peptidet består af aminosyresekvensen ifølge SEQ ID NO: 7, i hvilken 1 eller 2 aminosyrer er substituerede eller tilføjede.
18. Peptid ifølge krav 17, hvor den anden aminosyre fra N-terminus for aminosyresekvensen ifølge SEQ ID NO: 7 er phenylalanin, tyrosin, methionin eller tryptophan.
19. Peptid ifølge krav 17 eller 18, hvor C-terminalaminosyren i aminosyresekvensen ifølge SEQ ID NO: 7 er phenylalanin, leucin, isoleucin, tryptophan eller methionin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70326505P | 2005-07-27 | 2005-07-27 | |
PCT/JP2006/314947 WO2007013576A1 (en) | 2005-07-27 | 2006-07-21 | Colon cancer related gene tom34 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1910839T3 true DK1910839T3 (da) | 2016-07-04 |
Family
ID=37499354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06781857.5T DK1910839T3 (da) | 2005-07-27 | 2006-07-21 | Gen TOM34 i forbindelse med coloncancer |
Country Status (19)
Country | Link |
---|---|
US (1) | US8674059B2 (da) |
EP (1) | EP1910839B1 (da) |
JP (2) | JP5095603B2 (da) |
KR (2) | KR20130087639A (da) |
CN (1) | CN101278196B (da) |
AU (1) | AU2006273192B2 (da) |
BR (1) | BRPI0613970B8 (da) |
CA (1) | CA2616497C (da) |
CY (1) | CY1117839T1 (da) |
DK (1) | DK1910839T3 (da) |
ES (1) | ES2584247T3 (da) |
HK (1) | HK1115193A1 (da) |
HU (1) | HUE027330T2 (da) |
PL (1) | PL1910839T3 (da) |
PT (1) | PT1910839T (da) |
RU (2) | RU2449020C2 (da) |
SG (1) | SG163614A1 (da) |
SI (1) | SI1910839T1 (da) |
WO (1) | WO2007013576A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011008917A (es) * | 2009-03-04 | 2011-09-09 | Oncotherapy Science Inc | Peptidos vangl1 y vacunas que incluyen los mismos. |
TWI485245B (zh) * | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之melk胜肽及含此胜肽之疫苗 |
WO2012032763A1 (en) * | 2010-09-07 | 2012-03-15 | Oncotherapy Science, Inc. | Vangl1 peptides and vaccines including the same |
SG10201509823WA (en) | 2010-12-02 | 2015-12-30 | Oncotherapy Science Inc | TOMM34 Peptides And Vaccines Including The Same |
US9427461B2 (en) | 2011-10-28 | 2016-08-30 | Oncotherapy Science, Inc. | TOPK peptides and vaccines including the same |
US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
WO2016032230A1 (ko) * | 2014-08-26 | 2016-03-03 | (주)에이티젠 | Wls 단백질의 특정 모티프를 인지하는 항체 및 이를 포함하는 약제학적 조성물 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5785973A (en) * | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
ES2075196T3 (es) * | 1989-02-17 | 1995-10-01 | Chiron Mimotopes Pty Ltd | Metodo para el uso y la sintesis de peptidos. |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
US20030198642A1 (en) | 1995-08-03 | 2003-10-23 | Johannes J. Geuze | Cell derived antigen presenting vesicles |
US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
US7166573B1 (en) * | 1999-05-28 | 2007-01-23 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
EP1250145A4 (en) | 2000-01-03 | 2003-03-26 | Argonex Pharmaceuticals Inc | PEPTIDES DERIVED FROM ONCOGENE C-SKI FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER |
US7700359B2 (en) * | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
US20040181344A1 (en) | 2002-01-29 | 2004-09-16 | Massachusetts Institute Of Technology | Systems and methods for providing diagnostic services |
AU2003254950A1 (en) * | 2002-08-26 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | Peptides and drugs containing the same |
CA2511907A1 (en) * | 2003-01-06 | 2004-07-22 | Wyeth | Compositions and methods for diagnosing and treating colon cancers |
-
2006
- 2006-07-21 SI SI200632057A patent/SI1910839T1/sl unknown
- 2006-07-21 CN CN2006800353844A patent/CN101278196B/zh active Active
- 2006-07-21 ES ES06781857.5T patent/ES2584247T3/es active Active
- 2006-07-21 CA CA2616497A patent/CA2616497C/en active Active
- 2006-07-21 EP EP06781857.5A patent/EP1910839B1/en active Active
- 2006-07-21 SG SG201005112-6A patent/SG163614A1/en unknown
- 2006-07-21 PL PL06781857.5T patent/PL1910839T3/pl unknown
- 2006-07-21 AU AU2006273192A patent/AU2006273192B2/en active Active
- 2006-07-21 PT PT67818575T patent/PT1910839T/pt unknown
- 2006-07-21 DK DK06781857.5T patent/DK1910839T3/da active
- 2006-07-21 US US11/913,228 patent/US8674059B2/en active Active
- 2006-07-21 BR BRPI0613970A patent/BRPI0613970B8/pt not_active IP Right Cessation
- 2006-07-21 WO PCT/JP2006/314947 patent/WO2007013576A1/en active Application Filing
- 2006-07-21 RU RU2008107318/15A patent/RU2449020C2/ru active
- 2006-07-21 JP JP2008502763A patent/JP5095603B2/ja active Active
- 2006-07-21 HU HUE06781857A patent/HUE027330T2/en unknown
- 2006-07-21 KR KR1020137019800A patent/KR20130087639A/ko not_active Application Discontinuation
- 2006-07-21 KR KR1020087004601A patent/KR101325194B1/ko active IP Right Grant
- 2006-07-21 RU RU2011127868/15A patent/RU2526196C2/ru active
-
2008
- 2008-10-02 HK HK08111013.2A patent/HK1115193A1/zh not_active IP Right Cessation
-
2012
- 2012-01-27 JP JP2012015094A patent/JP2012125248A/ja active Pending
-
2016
- 2016-07-21 CY CY20161100717T patent/CY1117839T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1910839B1 (en) | 2016-04-27 |
SG163614A1 (en) | 2010-08-30 |
PT1910839T (pt) | 2016-07-14 |
SI1910839T1 (sl) | 2016-06-30 |
KR101325194B1 (ko) | 2013-11-06 |
CN101278196A (zh) | 2008-10-01 |
PL1910839T3 (pl) | 2016-11-30 |
HUE027330T2 (en) | 2016-09-28 |
US8674059B2 (en) | 2014-03-18 |
CA2616497C (en) | 2016-06-07 |
KR20130087639A (ko) | 2013-08-06 |
AU2006273192B2 (en) | 2011-09-01 |
RU2449020C2 (ru) | 2012-04-27 |
JP2009502732A (ja) | 2009-01-29 |
CY1117839T1 (el) | 2017-05-17 |
JP5095603B2 (ja) | 2012-12-12 |
RU2008107318A (ru) | 2009-09-10 |
EP1910839A1 (en) | 2008-04-16 |
CA2616497A1 (en) | 2007-02-01 |
AU2006273192A1 (en) | 2007-02-01 |
US20090214571A1 (en) | 2009-08-27 |
RU2011127868A (ru) | 2013-01-20 |
BRPI0613970B1 (pt) | 2019-10-29 |
KR20080040738A (ko) | 2008-05-08 |
JP2012125248A (ja) | 2012-07-05 |
BRPI0613970B8 (pt) | 2021-05-25 |
ES2584247T3 (es) | 2016-09-26 |
WO2007013576A1 (en) | 2007-02-01 |
CN101278196B (zh) | 2013-05-15 |
RU2526196C2 (ru) | 2014-08-20 |
BRPI0613970A2 (pt) | 2011-02-22 |
HK1115193A1 (zh) | 2008-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070054849A1 (en) | Method for diagnosing hepatocellular carcinomas | |
US20090136508A1 (en) | Method of diagnosing colon and gastric cancers | |
EP1907581A2 (en) | Method of diagnosing small cell lung cancer | |
JP2009502112A (ja) | 腎細胞癌を診断および処置するための方法 | |
DK1910839T3 (da) | Gen TOM34 i forbindelse med coloncancer | |
WO2007013360A2 (en) | Pancreatic cancer related gene cst6 and gabrp | |
EP1907859B1 (en) | Genes and polypeptides relating to prostate cancers | |
US8182997B2 (en) | Prostate cancer related gene STYK1 | |
WO2007013359A2 (en) | Cancer related gene rasgef1a | |
US20080199468A1 (en) | Method For Diagnosing Colorectal Cancers | |
MX2008001345A (es) | Gen tom34 relacionado con cancer de colon. |